

Background:

Concern has been raised regarding the potential contributions of veterinary antimicrobial use to increasing levels of resistance in bacteria critically important to human health¹. Canine pyoderma is a frequent, often recurrent diagnosis in pet dogs, usually attributable to secondary bacterial infection of the skin². Antimicrobials are recommended for lesion resolution^{3,4}.

Aims:

- To estimate pyoderma prevalence in a UK vet-visiting canine population.
- To describe case characteristics & treatment prescribed in a large number of dogs diagnosed with pyoderma in UK primary-care practice.



Methods:

Electronic patient record (EPR) data routinely collected in 2010 by UK primary-care veterinary clinics participating in VetCompass⁵ were used to identify dogs diagnosed with pyoderma.

Patient & prescribing data (one pyoderma episode per dog) were extracted. Additional case data were reviewed in a subset randomly selected for case validation.


Results:

Of 54,600 dogs presented to 73 participating practices in 2010, 683 (1.3%) had at least 1 recorded pyoderma diagnosis.

Superficial pyoderma was recorded most frequently (Table 1):


Recorded pyoderma type	Number of dogs	% of 90 dogs reviewed in detail
Surface	2	2.2
Superficial	37	41.1
Deep	6	6.7
Mixed (deep + other)	5	5.6
Unclear, ambiguous or absent clinical description	40	44.4
Total	90	100

Table 1: depth of pyoderma lesions in the 90 episodes reviewed in detail




Antimicrobials were dispensed in 97% of cases. Most dogs were prescribed systemic therapy (92%) (Figure 1).

Figure 1: Antimicrobial formulations initially prescribed within 24 hours of diagnosis in UK canine pyoderma cases



Agents most frequently prescribed were amoxicillin-clavulanate, cefalexin, clindamycin & cefovecin (Figure 2).

Figure 2: Systemic antimicrobial agents initially prescribed or administered within 24 hours of diagnosis in UK canine pyoderma cases



Systemic antimicrobials were prescribed for fewer than 14 days in around 40% of cases reviewed in detail (Figure 3).

Figure 3: Total estimated duration of treatment with the systemic antimicrobial agent initially selected

Prescribed daily doses were below minimum manufacturers recommended daily dose in 26% of 43 dogs with sufficient information for dose evaluation.

Conclusions:

- Antimicrobial prescribing behaviour for treatment of canine pyoderma was variable but frequently appeared inconsistent with current recommendations for clinically effective but prudent use^{3,4,6}.
- Use of clinical data from primary practice EPRs can provide valuable insight into common clinical conditions and associated prescribing.

Acknowledgements: Our thanks go to the participating practices for sharing their EPR data, to Peter Dron & to Noel Kennedy (RVC).

References

- Kock R, Becker K et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveillance. 2010 Oct 14;15(41):19688.
- Hill PB, Lo A et al: Survey of the prevalence, diagnosis and treatment of dermatological conditions in small animals in general practice. Vet. Record 2006, 158(16):533-539.
- Hillier A, Lloyd DH, et al: Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases). Vet.Dermatology 2014, 25(3):163-175, e142-163.
- Beco L, Guaguere E et al: Suggested guidelines for using systemic antimicrobials in bacterial skin infections (Part 2): antimicrobial choice, treatment regimens and compliance. Vet. Record 2013, 172(6):156-160.
- VetCompass Project: Health Surveillance for UK Companion Animals [http://www.rvc.ac.uk/VetCompass/Index.cfm]
- PROTECT poster (British Small Animal Veterinary Association & Small Animal Medicine Society advice on the use of antibiotics). [http://www.bsava.com/Resources/PROTECT.aspx]